share_log

騰盛博藥-B：股東週年大會適用的代表委任表格

BRII-B: FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING

Hong Kong Stock Exchange ·  Apr 25 04:44
Summary by Moomoo AI
腾盛博药-B（騰盛博藥生物科技有限公司）將於2024年6月25日透過卓佳電子會議系統線上舉行股東週年大會。會議將審議包括審核合併財務報表、董事及核數師報告在內的多項決議案。此外，會議還將涉及重選Zhi Hong博士為執行董事、Grace Hui Tang女士和Martin J Murphy Jr博士為獨立非執行董事，以及授權董事會釐定董事酬金。股東將對續聘德勤•關黃陳方會計師行為核數師及其酬金進行投票。董事會亦將尋求一般授權，以配發、發行及處理不超過已發行股份總數20%的額外股份，並購回不超過總數10%的股份。股東需於2024年6月23日前提交代表委任表格，並提供有效電郵地址以透過線上系統出席會議及投票。
腾盛博药-B（騰盛博藥生物科技有限公司）將於2024年6月25日透過卓佳電子會議系統線上舉行股東週年大會。會議將審議包括審核合併財務報表、董事及核數師報告在內的多項決議案。此外，會議還將涉及重選Zhi Hong博士為執行董事、Grace Hui Tang女士和Martin J Murphy Jr博士為獨立非執行董事，以及授權董事會釐定董事酬金。股東將對續聘德勤•關黃陳方會計師行為核數師及其酬金進行投票。董事會亦將尋求一般授權，以配發、發行及處理不超過已發行股份總數20%的額外股份，並購回不超過總數10%的股份。股東需於2024年6月23日前提交代表委任表格，並提供有效電郵地址以透過線上系統出席會議及投票。
TENSHENGBO PHARMACEUTICAL-B (TENSHENG BO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD.) WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 25, 2024 ONLINE VIA THE SUPERIOR ELECTRONIC CONFERENCE SYSTEM. The meeting will consider a number of resolutions including the review of the consolidated financial statements, directors' and auditor's reports. In addition, the meeting will involve the re-election of Dr. Zhi Hong as Executive Director, Ms. Grace Hui Tang and Dr. Martin J Murphy Jr as independent non-executive directors, and the authorization of the Board to determine directors' remuneration. Shareholders will vote on the renewal of Tak Kin Guan Wong Chan Fang as acting auditor and his remuneration. The Board of Directors will also seek general authorization to distribute, issue and process additional shares not exceeding 20% of the total issued shares and to repurchase no more than 10% of the total shares. Shareholders are required to submit the proxy form by 23 June 2024 and provide a valid email address to attend meetings and vote via the online system.
TENSHENGBO PHARMACEUTICAL-B (TENSHENG BO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD.) WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 25, 2024 ONLINE VIA THE SUPERIOR ELECTRONIC CONFERENCE SYSTEM. The meeting will consider a number of resolutions including the review of the consolidated financial statements, directors' and auditor's reports. In addition, the meeting will involve the re-election of Dr. Zhi Hong as Executive Director, Ms. Grace Hui Tang and Dr. Martin J Murphy Jr as independent non-executive directors, and the authorization of the Board to determine directors' remuneration. Shareholders will vote on the renewal of Tak Kin Guan Wong Chan Fang as acting auditor and his remuneration. The Board of Directors will also seek general authorization to distribute, issue and process additional shares not exceeding 20% of the total issued shares and to repurchase no more than 10% of the total shares. Shareholders are required to submit the proxy form by 23 June 2024 and provide a valid email address to attend meetings and vote via the online system.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more